(PDF/132.44 KB) Bicalutamide may cause sexual dysfunction, including decreased sex drive and erectile dysfunction.Similarly to in men, bicalutamide has been associated with minimal or no sexual dysfunction in women.At 5.3 years follow-up, the incidence of depression was 5.5% for bicalutamide monotherapy relative to 3.0% for placebo in the The most common side effects of bicalutamide monotherapy in men are breast pain/tenderness and gynecomastia.Bicalutamide reduces the size of the prostate gland and Antiandrogen therapy and estrogen therapy are known to produce demasculinizing and feminizing effects in the A few cases of photosensitivity (hypersensitivity to Antiandrogen therapy and estrogen therapy are known to produce demasculinizing and The incidence of diarrhea with bicalutamide monotherapy in the According to Iversen et al.
(PDF/142.97 KB) The frequent side effects of 150 mg bicalutamide are gynaecomastia and breast pain.
(PDF/132.6 KB)
(PDF/131.14 KB) If the site still contains content that does not yet reflect the withdrawal of the UK from the EU, this is unintentional and will be addressed.
(PDF/132.44 KB) Information on the morphological changes induced by 150 mg bicalutamide on prostate tissue components and lesions has been obtained in radical prostatectomy specimens. In the EU and a number of other countries, bicalutamide 150 mg/day is approved in men with locally advanced nonmetastatic … Zeneca Pharmaceuticals, Wilmington, DE. The United Kingdom (UK) withdrew from the European Union (EU) on 31 January 2020 and is no longer an EU Member State. (PDF/142.97 KB) (PDF/271.85 KB) (PDF/131.08 KB) (PDF/222.02 KB) (PDF/294.42 KB)
Following a request from Belgium, the European Medicines Agency's (EMEA's) Committee for Medicinal Products for Human Use (CHMP) has reviewed the available information on the effectiveness and safety of medicines containing 150 mg bicalutamide, used orally (by mouth) for the treatment of locally advanced prostate cancer.The Committee has concluded that the benefits of these products still outweigh their risks, but has recommended some changes to their prescribing information to ensure that they are prescribed only to patients who are at a high risk of disease progression.The CHMP has reviewed the data for all medicines containing bicalutamide 150 mg, both those that are authorised in the European Union, as well as those for which applications for authorisation are under review, for the treatment of locally advanced prostate cancer. reported a ≥50% PSA decline rate in 7/31 patients (22.5%), overall duration of response 4 months (3–13+ months). What Bicalutamide 150 mg is and what it is used for Bicalutamide belongs to the group of antiandrogens. This included data from clinical trials (third analysis of the main studies, after patients had been followed for over 7 years), reports of side effects and information published in scientific journals.The CHMP has concluded that the benefits of the use of bicalutamide 150 mg tablets in locally advanced prostate cancer still outweigh their risks in patients who are at high risk of their disease getting worse. (PDF/35.22 KB)